Cargando…

Adalimumab (Humira™) in Ophthalmology: A Review of the Literature

Tumor Necrosis Factor alpha (TNF-α) is a pleiotropic cytokine which plays a primary role in the induction of inflammation in autoimmune diseases. The newest anti-TNF-α agent is adalimumab (Humira, Abbott Pharmaceutical Inc.), a human-derived antibody. This review summarizes the characteristics of ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neri, Piergiorgio, Lettieri, Marta, Fortuna, Cinzia, Zucchi, Manuela, Manoni, Mara, Celani, Silvia, Giovannini, Alfonso
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2010
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991444/ https://www.ncbi.nlm.nih.gov/pubmed/21180427 http://dx.doi.org/10.4103/0974-9233.71588

Ejemplares similares

Inflammatory Choroidal Neovascularization
por: Neri, Piergiorgi, et al.
Publicado: (2009)

Adalimumab (Humira) induced acute lung injury
por: Kohli, Ritesh, et al.
Publicado: (2013)

Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab)
por: Tebbey, Paul W, et al.
Publicado: (2015)

Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®
por: Magnenat, Laurent, et al.
Publicado: (2016)

Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®
por: Zhang, Erhui, et al.
Publicado: (2020)

Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®)
por: Kwon, Joon-Cheol, et al.
Publicado: (2021)

Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects
por: Hyland, Elizabeth, et al.
Publicado: (2016)

The Expiry of Humira(®) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
por: Moorkens, Evelien, et al.
Publicado: (2021)

Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects
por: Hillson, Jan, et al.
Publicado: (2018)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
por: Fleischmann, Roy M., et al.
Publicado: (2018)

Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study
por: Van den Bosch, Filip, et al.
Publicado: (2017)

Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study
por: Van den Bosch, Filip, et al.
Publicado: (2017)

Adalimumab (Humira®) Induced Recurrent Peritonsillar Abscess in A Patient Received Three Different Anti-TNF Therapies: A Case Report
por: Vural, Sevilay, et al.
Publicado: (2022)

Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy
por: Sinha, Shubhadeep, et al.
Publicado: (2020)

A prospective, randomized, double‐blind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis
por: Jani, Rajendrakumar H., et al.
Publicado: (2015)

Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients’ satisfaction: a cross-sectional survey by patient organisations
por: Kaneko, Kayoko, et al.
Publicado: (2022)

Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial
por: Su, Jinmei, et al.
Publicado: (2020)

Design and Evaluation of a Multiplexed Assay to Assess Human Immunogenicity Against Humira®
por: Alleyn, Matthew, et al.
Publicado: (2020)

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
por: Fleischmann, Roy M., et al.
Publicado: (2021)

Clinical Evaluation of Humira(®) Biosimilar ONS-3010 in Healthy Volunteers: Focus on Pharmacokinetics and Pharmacodynamics
por: Dillingh, Marlous R., et al.
Publicado: (2016)

Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
por: Cohen, Stanley B, et al.
Publicado: (2018)

Similar Pharmacokinetics of the Adalimumab (Humira(®)) Biosimilar BI 695501 Whether Administered via Subcutaneous Autoinjector or Prefilled Syringe (VOLTAIRE(®)-AI and VOLTAIRE(®)-TAI): Phase 1, Randomized, Open-Label, Parallel-Group Trials
por: Ramael, Steven, et al.
Publicado: (2018)

A Patients' Perspective Towards the Injection Devices for Humira® and Imraldi® in a Nationwide Switching Program
por: Karlsdottir, Kristin, et al.
Publicado: (2022)

Combined therapy with intravitreal aflibercept and subtenon corticosteroids in eyes with severe diabetic papillopathy: two case reports
por: Arapi, Ilir, et al.
Publicado: (2021)

A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis
por: Jamshidi, Ahmadreza, et al.
Publicado: (2017)

Erythropoietin in ophthalmology: A literature review
por: Abri Aghdam, Kaveh, et al.
Publicado: (2016)

Adalimumab-Induced Lupus Nephritis: Case Report and Review of the Literature
por: Kazzi, Brigitte, et al.
Publicado: (2022)

Dental Occlusion and Ophthalmology: A Literature Review
por: Marchili, Nicola, et al.
Publicado: (2016)

Pulmonary Sarcoidosis Induced by Adalimumab: A Case Report and Literature Review
por: Sim, Jae Kyeom, et al.
Publicado: (2016)

Adalimumab-Induced Lupus Serositis: A Case Report and Review of the Literature
por: Lee, Sandy, et al.
Publicado: (2023)

Improved production of Humira antibody in the genetically engineered Escherichia coli SHuffle, by co-expression of human PDI-GPx7 fusions
por: Lénon, Marine, et al.
Publicado: (2020)

Honorary Authorships in the Ophthalmological Literature
por: Hardjosantoso, Hannah C., et al.
Publicado: (2020)

A Case of Goldenhar Syndrome Associated with a New Retinal Presentation: Exudative Vitelliform Maculopathy
por: Bruè, Claudia, et al.
Publicado: (2015)

Comment on the Article “Adalimumab-Induced Lupus Nephritis: Case Report and Review of the Literature”
por: Drosos, Alexandros A., et al.
Publicado: (2023)

Adalimumab-induced systemic lupus erythematosus: A case report and review of the literature
por: Landells, Fiona M, et al.
Publicado: (2023)

Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature
por: Moshirfar, Majid, et al.
Publicado: (2018)

Quarterly Report of Ophthalmological and Otological Literature
por: Gardiner, E. J.
Publicado: (1881)

Quarterly Abstract of Ophthalmological and Otological Literature
por: Gardiner, E. J.
Publicado: (1881)

Adalimumab in the treatment of cardiac sarcoidosis: Single center case series and narrative literature review
por: Sweis, Jaleel Jerry G., et al.
Publicado: (2022)

The broad spectrum of application of optical coherence tomography angiography to the anterior segment of the eye in inflammatory conditions: a review of the literature
por: Pichi, Francesco, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gt2guvs7bsj97c474jag0e7llc